Intravenous Lidocaine Infusion Versus Intravenous Dexmedetomidine Infusion During Sleeve Gastrectomy

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age20-50
SponsorAlexandria University

About this trial

Although laparoscopic (LAP) bariatric surgery is minimally invasive. Following any laparoscopic procedure, patients typically experience the peak of postoperative pain within the first 24 hours. This intense pain gradually subsides, with significant relief usually occurring by the 2nd or 3rd postoperative day. The initial peak and subsequent decline in pain intensity highlight the importance of effective early pain management strategies to ensure patient comfort and recovery during this critical period. Inadequate management of postoperative pain can result in serious complications. Lidocaine is increasingly recognised as a vital adjunct in managing perioperative pain. Its efficacy extends beyond traditional local anaesthetic applications, as it also demonstrates analgesic, anti-hyperalgesic, and anti-inflammatory properties. Dexmedetomidine is a highly selective alpha-2 adrenergic agonist with hypnotic, sedative, anxiolytic, sympatholytic, and analgesic effects, while causing minimal respiratory depression

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Age: 20-50 years, both sexes.

American Standards Association (ASA) physical status class II to III.

Body mass index (BMI) 35-50 kg m-².

Disqualifiers

Cardiac conduction disorders.

Cardiomyopathy.

Chronic opioid use.

Allergy to the studied medications.

Trial design

Design model

Parallel

Treatments tested in this trial

  • intravenous lidocaine

    Other intervention

    20 patients will receive lidocaine infusion

  • intravenous dexmedetomidine

    Other intervention

    20 patients will receive dexmedetomidine infusion

Treatment groups

40 Participants
are divided into 2 treatment groups
Group A: group LActive comparator 1 intervention
Group B: group DActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

visual analogue scale

at rest , movement

Time frame
postoperative day 1

Secondary outcomes

1

time to first nalbuphine dose

minutes

Time frame
postoperative day 1
2

patient satisfaction

• Poor = 1, fair = 2, good = 3, excellent = 4.

Time frame
postoperative day1
3

postoperative nalbuphine requirements

mg

Time frame
postoperative day 1
4

postoperative complications

nausea , vomiting

Time frame
postoperative day 1

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.